TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05978063
Drug: difelikefalin 1.0 mg tablets
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral difelikefalin 1.0 mg administered twice daily
Study: NCT05978063
Drug: difelikefalin 0.25 mg tablets
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral difelikefalin 0.25 mg administered twice daily
Study: NCT05613140
Drug: sacubitril/valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
Study: NCT06548230
Drug: Nadunolimab
Normalized name: Nadunolimab
DrugBank: Nadunolimab (DB18249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Give by IV
Study: NCT06548230
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT06548230
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by mouth (PO
Study: NCT05168839
Drug: FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist.~The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera.~A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits.~An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded.
Study: NCT05818085
Drug: ABP-671
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low, medium or high dose (Part 1); Selected dose(s) (Part 2)
Study: NCT05818085
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout
Study: NCT06332274
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV.
Study: NCT05712343
Drug: Valacyclovir group
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
Study: NCT05521828
Drug: Follitropin delta (Rekovelle)
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 mcg/day will be used for ovarian stimulation in both arms
Study: NCT05521828
Drug: Duphaston
Normalized name: Duphaston
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/day will be used for pituitary suppression in both arms
Study: NCT05521828
Drug: GnRH agonist (Gonapeptyl)
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (2 ampules:0.2 mg) will be used for ovulation triggering in both arms
Study: NCT05741528
Drug: SEP-363856
Normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856 tablet
Study: NCT05848128
Drug: 5% Tavilermide ophthalmic solution
DrugBank: Tavilermide (DB12441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day topicial dosing
Study: NCT05159440
Drug: TORL-2-307-MAB
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
DrugBank: TORL-2-307 (DB18376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monoclonal antibody
Study: NCT05551182
Drug: Nicergoline
Normalized name: nicergoline
DrugBank: Nicergoline (DB00699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
Study: NCT06268704
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a non-particulate steroid commonly used to treat SI joint pain.
Study: NCT06268704
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a particulate steroid commonly used to treat SI joint pain.
Study: NCT06268704
Drug: 2% Lidocaine HCl Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.
Study: NCT05893888
Drug: PRV211 (Intraoperative Cisplatin System)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
Study: NCT05893888
Drug: PRV111 (Cisplatin Transmucosal System)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.
Study: NCT06135805
Drug: Fluocinonide 0,05% oral gel
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of Fluocinonide oral gel on oral syntomatic lesions
Study: NCT04825678
Drug: Erenumab
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
Study: NCT05367778
Drug: HS-10370
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10370 will be administered orally once daily in a continuous regimen
Study: NCT04780061
Drug: Vitamin D3 50,000 IU
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
Study: NCT05520255
Drug: 18F-PSMA-1007
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-PSMA-1007 intravenous injection
Study: NCT04327700
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
Study: NCT06285396
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine in solution, at applicable concentrations based on literature.
Study: NCT06285396
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine, at applicable concentrations based on literature.
Study: NCT06285396
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin, at applicable concentrations based on literature.
Study: NCT06273774
Drug: MK-8189
Normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06655376
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81-100 mg, oral
Study: NCT06655376
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.
Study: NCT06654011
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 260 mg/m², IV infusion, Q3W
Study: NCT06654011
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg, IV infusion, Q3W
Study: NCT06596512
Drug: MART
Normalized name: MART1
DrugBank: humanized SMART Anti-IL-12 Antibody (DB05848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are instructed to use prescribed study ICS/LABA for maintenance and as needed for rescue.
Study: NCT06590974
Drug: Freeze-dried Human Protein C Concentrate
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried Human Protein C Concentrate (TAK-662) intravenous injection
Study: NCT06603974
Drug: Benmelstobart
Normalized name: Benmelstobart
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg, diluted to 250ml with normal saline, infusion time 60 ± 10mins. The first day of each cycle, 3 weeks (21 days) as a treatment cycle
Study: NCT06603974
Drug: tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: it needs to be administered according to the patient\&#39;s body surface area\&lt; 40mg / time at 1.25m2; \&gt; 50mg/ time for 1.25m2 and \&lt;1.5m2; \&gt; 60mg/ time at 1.5m2; Oral, twice a day, after morning and evening meals, for 14 consecutive days, rest for 7 days, as a treatment cycle; Repeat every 3 weeks;
Study: NCT06603974
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2, administered on the first day of each cycle, repeated every 3 weeks;
Study: NCT06603974
Drug: albumin paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, administered on the first and eighth days of each cycle
Study: NCT06595186
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide will be administered.
Study: NCT06596122
Drug: Vitamin D (Cholecalciferol )
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In conjunction with the AC-T chemotherapy protocol, individuals in the intervention group who have a vitamin D deficiency will receive an oral loading dose of 50,000 IU weekly for eight weeks. Subsequently, they will be given 100,000 IU monthly until the completion of their chemotherapy treatment.
Study: NCT04912869
Drug: Crovalimab
Normalized name: Crovalimab
DrugBank: Crovalimab (DB16128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).
Study: NCT06594224
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.
Study: NCT06083038
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive standard of care alpelisib
Study: NCT06531798
Drug: Breztri Aerosphere
Normalized name: Breztri Aerosphere
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg
Study: NCT05548582
Drug: OxyCODONE 5 mg Oral Tablet
Normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No opioid prescription after laparoscopic hysterectomy
Study: NCT06412471
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT06412471
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: chemotherapy
Study: NCT06412471
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy
Study: NCT06412471
Drug: Paclitaxel-albumin
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy
Study: NCT05578664
Drug: Pembrolizumab injection plus metastasis directed treatment (surgery or RT)
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
Study: NCT05637086
Drug: Pentoxifylline 400 MG
Normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
Study: NCT06592352
Drug: Modafinil Generis 100 mg
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants enrolled in the study will receive the study intervention drug (Modafinil Generis 100 mg). Dose 200 mg once per day (2 tablets of 100 mg) in the morning for 3 months (84 days), Oral administration
Study: NCT06590207
Drug: plasma rich with WNV neutralizing antibodies
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml plasma of the convalescents: produced in the blood bank, from the blood of Sheba workers who participated in the SPRI study (Helsinki 0196-23) and whose blood was found to have neutralizing antibodies to WNV above 1:524. The blood units from the volunteers who will donate will meet all the requirements of a normal blood donation and will only include men or women who were not pregnant, and the units will pass all the tests accepted at the blood bank before donation.
Study: NCT06590207
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT06590714
Drug: Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
Study: NCT05879458
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg QD for 8 weeks followed by 100 mg for 16 weeks
Study: NCT05282901
Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution
Normalized name: Pembrolizumab 25 MG/1 ML Intravenous Solution
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.
Study: NCT06373640
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of vancomycin
Study: NCT06590831
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: to compare between efficacy of lactoferrin alone and lactoferrin with iron for treatment of iron deficiency anemia during 3rd trimester of pregnancy
Study: NCT06595576
Drug: Cannabis - Placebo Dose (0 mg)
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume placebo cannabis edibles.
Study: NCT06595576
Drug: Cannabis - Low Dose (2 mg)
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume a low dose (2 mg) of cannabis edibles.
Study: NCT06595576
Drug: Cannabis - Medium Dose (10 mg)
Normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume a medium dose (10 mg) of cannabis edibles.
Study: NCT06595576
Drug: Cannabis - High Dose (20 mg)
Normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume a high dose (20 mg) of cannabis edibles.
Study: NCT06263010
Drug: Allopregnanolone
Normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.
Study: NCT06591494
Drug: Quadruple therapy with sodium bicarbonate instead of bismuth
Normalized name: Neut brand of sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20 mg BID Sodium bicarbonate 500 mg TID Amoxicillin 1 g BID Clarithromycin 500 mg BID
Study: NCT06537414
Drug: Daplusiran/Tomligisiran Dose Level 1
DrugBank: Tomligisiran (DB19330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daplusiran/Tomligisiran dose level 1 will be administered
Study: NCT06537414
Drug: Daplusiran/Tomligisiran Dose Level 2
DrugBank: Tomligisiran (DB19330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daplusiran/Tomligisiran dose level 2 will be administered
Study: NCT05635110
Drug: VX-548
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT05635110
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT05635110
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration.
Study: NCT05941494
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
Study: NCT05941494
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
Study: NCT05941494
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
Study: NCT05941494
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
Study: NCT05707819
Drug: Sintilimab (PD-1 Antibody)
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
Study: NCT04681469
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months.
Study: NCT06265389
Drug: Pentoxifylline Oral Tablet
Normalized name: pentoxifylline Oral Tablet
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
Study: NCT04818034
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
Study: NCT05433116
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
Study: NCT05433116
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20mg once daily orally, start concomitant to cycle 2 of pembrolizumab